Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DiGeorge syndrome critical region gene 11 (DGCR11) is a long non-coding RNA (lncRNA) gene located in the 22q11.2 chromosomal region—a locus associated with DiGeorge syndrome and related chromosomal deletion syndromes. DGCR11 does not encode a protein; instead, as a non-coding RNA, it may have regulatory roles in gene expression. There is very limited published functional or clinical information on DGCR11; it is not established as a therapeutic target, marker, or mechanistically implicated molecule in disease beyond being a genomic feature of the 22q11.2 region[7]. Most referenced "DiGeorge syndrome critical region" genes (e.g., DGCR2, DGCR6, DGCR8) are protein-coding and functionally characterized, while DGCR11 currently lacks similar biological or pharmacological validation[7]. The gene symbol DGCR11 refers to a non-coding RNA and not to a protein-coding receptor, transporter, or enzyme[7]. It does not appear in lists of well-characterized protein-coding genes implicated in therapeutic pharmacology or approved drug targets. Many clinical and genetic reviews of the 22q11.2 region and DiGeorge syndrome do not mention DGCR11 as functionally relevant[1]. DGCR11 is often mistaken due to similarity with other DiGeorge syndrome region genes such as DGCR2 or DGCR8, which are protein-coding and have documented biological roles and disease associations[1][2][5][8]. Most information online about "DiGeorge syndrome critical region" genes concerns these protein-coding genes, not DGCR11. Summary: DGCR11 (DiGeorge syndrome critical region gene 11) is a non-protein coding RNA gene of uncertain function and unknown therapeutic relevance; it is not a current drug target. This target name is often confused with functionally validated genes elsewhere in the 22q11.2 region[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DiGeorge syndrome critical region gene 11 (non-protein coding) (DGCR11).